CL2021002901A1 - Nuevas endolisinas de gardnerella y usos de las mismas - Google Patents

Nuevas endolisinas de gardnerella y usos de las mismas

Info

Publication number
CL2021002901A1
CL2021002901A1 CL2021002901A CL2021002901A CL2021002901A1 CL 2021002901 A1 CL2021002901 A1 CL 2021002901A1 CL 2021002901 A CL2021002901 A CL 2021002901A CL 2021002901 A CL2021002901 A CL 2021002901A CL 2021002901 A1 CL2021002901 A1 CL 2021002901A1
Authority
CL
Chile
Prior art keywords
endolysins
gardnerella
novel
diseases
treatment
Prior art date
Application number
CL2021002901A
Other languages
English (en)
Inventor
Lorenzo Corsini
Original Assignee
Phagomed Biopharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phagomed Biopharma Gmbh filed Critical Phagomed Biopharma Gmbh
Publication of CL2021002901A1 publication Critical patent/CL2021002901A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Se describen endolisinas de fago selectivas de especies recombinantes (endolisinas de dominio intercambiado); a su uso en el tratamiento de enfermedades, tales como infecciones bacterianas, como la vaginosis bacteriana; polinucleótidos que las codifican; una composición farmacéutica que las para su uso en el tratamiento de tales enfermedades, donde dichas endolisinas, polinucleótidos y composición farmacéutica pueden administrarse localmente (dentro de la vagina).
CL2021002901A 2019-05-08 2021-11-04 Nuevas endolisinas de gardnerella y usos de las mismas CL2021002901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19173389 2019-05-08

Publications (1)

Publication Number Publication Date
CL2021002901A1 true CL2021002901A1 (es) 2022-06-03

Family

ID=66476422

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002901A CL2021002901A1 (es) 2019-05-08 2021-11-04 Nuevas endolisinas de gardnerella y usos de las mismas

Country Status (14)

Country Link
US (1) US20220315908A1 (es)
EP (1) EP3969578A1 (es)
JP (2) JP2022532130A (es)
KR (1) KR20220007123A (es)
CN (2) CN120136980A (es)
AU (2) AU2020268752B2 (es)
BR (1) BR112021022283A2 (es)
CA (1) CA3136346A1 (es)
CL (1) CL2021002901A1 (es)
IL (1) IL287842A (es)
MA (1) MA55951A (es)
MX (1) MX2021013491A (es)
SG (1) SG11202111067YA (es)
WO (1) WO2020225335A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4247943A1 (en) * 2020-11-18 2023-09-27 CC Biotech Ltd. Polypeptides for treatment of bacterial infections
WO2023083434A1 (en) * 2021-11-09 2023-05-19 BioNTech SE Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
CN118804761A (zh) 2022-02-11 2024-10-18 生物技术公司 加德纳菌内溶素的新型治疗用途
DE102022213056A1 (de) 2022-12-05 2024-06-06 Universität Rostock, Körperschaft des öffentlichen Rechts Innovative antimikrobielle Therapie gegen Streptococcus pneumoniae mittels mRNA kodierter Bakteriophagen-Endolysine/Autolysine
CN121079100A (zh) 2023-05-09 2025-12-05 百欧恩泰欧洲股份公司 加德纳菌属内溶素的阴道内制剂
WO2025002339A1 (zh) * 2023-06-30 2025-01-02 上海赛增医疗科技有限公司 新型工程裂解酶及其用途
WO2025024827A1 (en) * 2023-07-27 2025-01-30 Topaz Biosciences, Inc. Cell wall hydrolases targeting c. acnes
KR20260049580A (ko) 2023-07-27 2026-04-14 토파즈 바이오사이언시스, 인크. 씨. 아크네스를 표적화하는 세포벽 가수분해효소
TW202541833A (zh) 2023-12-12 2025-11-01 德商拜恩技術股份公司 包含內溶素之組合物及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202556D0 (en) * 2002-02-04 2002-03-20 Danisco Novel Protein
DK2037946T3 (en) * 2006-05-05 2015-04-27 Gangagen Inc ANTIMICROBIAL ACTIVITIES DERIVED BY PHAGER
AU2008328584A1 (en) * 2007-11-26 2009-06-04 Plant Bioscience Limited Novel polypeptides having endolysin activity and uses thereof
US20120171188A1 (en) * 2008-08-19 2012-07-05 Hyglos Invest Gmbh Artificial Peptidoglycan Lysing Enzymes and Peptidoglycan Binding Proteins
EP2157100A1 (en) * 2008-08-19 2010-02-24 Profos AG Artificial peptidoglycan lysing enzymes and peptidoglycan binding proteins
GB0815484D0 (en) * 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
SG178440A1 (en) * 2009-08-24 2012-04-27 Univ Leuven Kath New endolysin obpgplys
EP2338916A1 (en) * 2009-12-23 2011-06-29 Hyglos Invest GmbH Chimeric polypeptides and their use in bacterial decoloniation
EA037276B1 (ru) * 2010-04-27 2021-03-03 Лисандо Аг Способы устранения или уменьшения бактериальной биопленки
GB201018518D0 (en) * 2010-11-03 2010-12-15 Univ Leuven Kath Novel endolysin
EP2468856A1 (en) * 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
US8790639B2 (en) * 2012-03-28 2014-07-29 The United States Of America, As Represented By The Secretary Of Agriculture Enhanced antimicrobial lytic activity of a chimeric Ply187 endolysin
SG11201707345VA (en) * 2015-03-12 2017-10-30 Micreos Human Health Bv Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection
CN105062992B (zh) * 2015-07-20 2018-05-11 昆明理工大学 一种细胞内溶素和编码此细胞内溶素的多核苷酸
AU2018248060B2 (en) * 2017-04-03 2024-05-23 Sasinapas Co., Ltd. Engineered Gram-negative endolysins
CN111471671B (zh) * 2020-04-16 2022-04-12 中国农业大学 一种具有抑制产气荚膜梭菌活性的蛋白质及其相关生物材料与应用
CN118804761A (zh) * 2022-02-11 2024-10-18 生物技术公司 加德纳菌内溶素的新型治疗用途

Also Published As

Publication number Publication date
CN120136980A (zh) 2025-06-13
SG11202111067YA (en) 2021-11-29
MA55951A (fr) 2022-03-23
US20220315908A1 (en) 2022-10-06
AU2020268752B2 (en) 2025-12-18
CN113795577A (zh) 2021-12-14
AU2020268752A1 (en) 2021-12-02
EP3969578A1 (en) 2022-03-23
IL287842A (en) 2022-01-01
JP2022532130A (ja) 2022-07-13
BR112021022283A2 (pt) 2021-12-28
WO2020225335A1 (en) 2020-11-12
CN113795577B (zh) 2025-03-18
MX2021013491A (es) 2022-02-21
KR20220007123A (ko) 2022-01-18
AU2026201469A1 (en) 2026-03-19
CA3136346A1 (en) 2020-11-12
JP2025026484A (ja) 2025-02-21

Similar Documents

Publication Publication Date Title
CL2021002901A1 (es) Nuevas endolisinas de gardnerella y usos de las mismas
CL2022003510A1 (es) Inhibidores de cisteína proteasas y sus métodos de uso
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
HN2011001195A (es) Compuestos que expanden las celulas madre hematopoieticas
MX2019010171A (es) Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular.
MX2015010190A (es) Metodos de tratamiento topico para infecciones microbianas.
MX2018005194A (es) Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas.
BR112015026122A8 (pt) agente de polietileno glicol-il-10 (peg-il-10), seu uso, composição farmacêutica, contentor estéril e kit
MX2019002962A (es) Inhibidores espirobiciclicos de la interaccion de menina-mll.
CR20140475A (es) Agentes terapéuticos para administración subcutánea optimizados
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
MX2019004402A (es) Metodos para el tratamiento de las condiciones relacionadas con la inflamacion utilizando moduladores antiinflamatorios y metabolicos pluripotentes.
MX2023009921A (es) Formulaciones de proteinas de fusion ace2-fc.
CL2024001961A1 (es) Proteína de fusión permeable a la barrera hematoencefálica y usos de ésta
CL2016001130A1 (es) Composiciones sólidas de triglicéridos y usos de estas
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2019004736A (es) Mini-tabletas de melatonina y metodos de fabricacion de las mismas.
MX2021008303A (es) Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa.
CL2021002430A1 (es) Formulación de tableta vaginal
MX2016005227A (es) Polipéptidos de acción prolongada y métodos para su producción y administración.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
AR106739A1 (es) Uso de una cantidad terapéuticamente eficaz de un derivado clostridial para la preparación de una composición farmacéutica para el tratamiento de la incontinencia urinaria
PE20130659A1 (es) Dispositivos intravaginales que comprenden agentes anticolinergicos y metodos para prepararlos
PE20160649A1 (es) Pidotimod para el uso en el tratamiento de enfermedades asociadas con la inflamacion
CO2023007563A2 (es) Inmunocitoquina para activar el receptor il-10ra humano y su uso